Synovial chondromatosis extending to the ear canal: An unusual cause of conductive hearing loss.

J Stomatol Oral Maxillofac SurgFeb 20, 2026 (epub)
Case ReportOtolaryngology (ENT)

Rony Mollot, Jean Philippe Giot, Loric Galmard et al.

✦ AI-curated · Sources linked

Case in brief

A 70-year-old woman presented with progressive right-sided conductive hearing loss and painless preauricular swelling. Examination showed stenosis of the external auditory canal, audiometry confirmed conductive hearing loss, and imaging revealed numerous calcified nodules, suggesting temporomandibular joint synovial chondromatosis extending toward the ear canal. Surgical excision by arthrotomy removed the chondromas completely. Histopathology confirmed synovial chondromatosis, and postoperative pure-tone audiometry showed normalization of hearing.

What made this case unusual

The temporomandibular joint lesion extended to the external auditory canal, causing stenosis and conductive hearing loss—an exceptionally rare association described in the report.

Diagnostic / clinical pearl

In unexplained conductive hearing loss with preauricular swelling or external auditory canal stenosis, consider temporomandibular joint pathology, including synovial chondromatosis.

Source

PubMed · PMID 41724268

Published in J Stomatol Oral Maxillofac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.